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Recent reports suggest that anabolic steroid use might deleteri-
ously affect left ventricular function. To examine this possibility, 
the present study measured left ventricular size and function with 
use of Doppler echocardiographic techniques in 23 weight Iifters: 
12 who were currently using anabolic steroids and 11 who 
reported that they had never used these drugs. Drug users had 
administered anabolic steroids to themselves for at least three 
cycles over the past year. All studies were interpreted by blind 
review and group assignment was confirmed by urine testing. 
Average age, years of exercise training and body weight, as well as 
heart rate and blood pressure at rest were similar in both groups. 
Cardiac dimensions (mean ± SD) including left ventricular 
diastolic cavity diameter (57 ± 3 vs. 56 ± 5 mm), septal thickness 
(10 ± 2 vs. 9 ± 1 mm), posterior wall thickness (8 ± 1 vs. 8 ± 
1 mm) and myocardial mass (149 ± 27 vs. 135 ± 21 g) did not 
The use of anabolic steroids by athletes has received exten-
sive media attention. Evidence that these drugs can increase 
skeletal muscle mass and strength is controversial because 
approximately equal numbers of studies (1-3) conclude that 
the drugs do or do not increase muscle size and strength. 
However, their effectiveness is generally accepted in the 
athletic community and their use is reportedly widespread 
(4). These compounds have been associated with adverse 
effects on hepatic, reproductive and emotional function in 
therapeutic trials of patients and in limited research with 
athletes (5). Preliminary evidence also suggests that anabolic 
steroids may produce abnormalities in left ventricular dias-
tolic function. Resistance exercise training such as weight 
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differ between the anabolic steroid users and nonusers, respec-
tively. Left ventricular systolic and diastolic function at rest were 
also similar in the users and nonusers: left ventricular fractional 
shortening (38 ± 5% vs. 41 ± 5%); peak rate of wall thickening 
(4.3 ± 1.1 vs. 4 ± 1.1 s-1) and thinning ( -5.9 ± 1.6 vs. - 5.6 ± 
2.1 s-1); left ventricular filling rate (3.1 ± 0.6 vs. 3.3 ± 0.5 s-1), 
as well as early (81 ± 12 vs. 83 ± 12 cm/s) and atrial maximal 
inflow velocities (41 ± 6 vs. 41 ± 9 cm/s) and their ratio (2.01 ± 
0.49 vs. 2.16 ± 0.67) were not different between groups. 
These results suggest that anabolic steroid use was not associ-
ated with left ventricular hypertrophy or clinically detectable 
systolic and diastolic dysfunction in a small sample of weight 
lifters who were using these drugs. 
(1 Am Coli Cardio/1992;19:278-82) 
lifting increases left ventricular wall thickness and mass but 
does not affect diastolic function (6). In contrast, weight 
lifters who used anabolic steroids demonstrated reductions 
in diastolic filling suggestive of decreased left ventricular 
compliance in one study (7) that included only five athletes 
who used these drugs. In the present study we performed 
echocardiographic and Doppler measurements to evaluate 
cardiac size and function in 23 weight-trained athletes: 12 
who were currently using anabolic steroids and 11 who had 
never used these drugs. 
Methods 
Study subjects. Subjects were recruited by personal con-
tact and advertising in local weight-training facilities. Twen-
ty-five male weight lifters were initially recruited and pro-
vided informed written consent, as approved by the Clinical 
Research Review Board of The Miriam Hospital and The 
University of Rhode Island. Thirteen men reported current 
self-administration of anabolic steroids and 12 reported that 
they had never used these drugs. All 25 subjects had 
regularly engaged in weight lifting for at least 3 years. For 
admission to the study, athletes in the steroid group were 
required to have used the drugs for at least three cycles 
within the past year; a cycle was defined as 6 to 10 weeks of 
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steroid use followed by 4 to 6 weeks of abstinence from these 
drugs. 
Subjects completed medical history forms concerning 
steroid use, weight-training experience, exercise routines 
and maximal strength performance. Steroid users were 
asked to list the drug name and dose, as well as the schedule 
and length of their current cycle. 
Protocol. Height, weight, body circumference measure-
ments, heart rate at rest and blood pressure while seated 
were determined in each subject. Chest, abdomen, thigh, 
subscapular, triceps, suprailiac and axillary skinfolds were 
measured. Subjects then underwent an M-mode, two-
dimensional and Doppler echocardiographic study including 
color flow imaging with a phased array system (Hewlett-
Packard, Sonos 500) with use of either a 2.5 or a 3.5 MHz 
transducer (8). Urine samples were obtained on the same 
day as the echocardiographic study to verify group assign-
ment. Urine samples were frozen to -70°C and shipped by 
overnight mail to the Paul Ziffren Olympic Analytical Lab-
oratory, University of California at Los Angeles Medical 
Center. There the samples were analyzed with use of the 
standard gas chromatography-mass spectrometry tech-
niques employed to detect drug use in competitive athletes 
(9). 
Echocardiographic measurements. Two-dimensionally 
guided M-mode measurements of left and right ventricular 
and left atrial dimensions were obtained with subjects in the 
supine or left lateral decubitus position. Left ventricular 
dimensions and wall thickness were measured at the mid-
ventricular level of the parasternal long-axis view. Three 
cardiac cycles were measured and averaged for each vari-
able. American Society of Echocardiography standards (10) 
were followed for all echocardiographic measurements. 
End-diastole was determined by the peak of the R wave. The 
point of the smallest cavity internal area was used to 
determine end-systole. Left ventricular percent fractional 
shortening was calculated as the left ventricular end-
diastolic diameter minus the end-systolic diameter divided 
by left ventricular end-diastolic diameter. 
Total left ventricular area (AT) and the area comprising 
the left ventricular cavity (AC) were measured by planimetry 
and myocardial area (AM) calculated as AM = AT - AC. 
Three cardiac cycles were also digitized with use of the left 
ventricular apical four-chamber view to measure left ventric-
ular diastolic cavity length (L). Left ventricular mass (11) 
was calculated as 5/6 x 1.055 (AT- AC)L. The endocardial 
and epicardial borders of the left ventricle were digitized and 
differentiated to yield normalized peak rates of posterior wall 
thickening, cavity shortening, posterior and septal wall 
thinning and cavity enlargement (8). 
Continuous wave and pulsed Doppler examinations were 
performed with use of the lowest wall filter settings to record 
the optimal definition of the spectral envelope. Left ventric-
ular inflow velocities were obtained in the apical four-
chamber view by placing the Doppler sample volume at the 
tip of the mitral valve leaflets. 
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Transmitral inflow velocities were recorded to evaluate 
left ventricular diastolic filling variables. Doppler velocity 
curves of three cardiac cycles were digitized with the dedi-
cated computer analysis package of the Hewlett-Packard 
echocardiography system. The following measurements of 
left ventricular filling velocity were obtained: early peak flow 
velocity (Emax), early flow velocity integral (Ei), peak atrial 
flow velocity (AmaJ and atrial flow velocity integral (AJ In 
addition, the ratio of EmaxfAmax and E/Ai were calculated. 
Acceleration and deceleration times were measured as the 
time required for the early flow velocity to increase from 
zero to its peak and to decrease from its peak to baseline. 
Recordings from steroid users and nonusers were re-
viewed at random by a reader who did not know which 
subjects were using anabolic steroids. All echocardiographic 
and Doppler measurements in 10 subjects were made in 
triplicate and on three separate occasions by the same 
experienced reviewer. Reproducibility of the three measure-
ments was evaluated with analysis of variance techniques 
(12). Measurement error for all variables expressed as a 
percent of the mean ranged from 3.4 for left atrial size to 13.4 
for acceleration time; intraclass correlations ranged from 
0. 72 for acceleration time to 0.98 for heart rate. These results 
demonstrate reader reliability. 
Statistical analysis. The t test for independent samples 
was used in analyzing the difference between the mean 
values of the two groups. Data were tested for normality 
with use of Shapiro and Wilk's W statistic (13). Data 
violating the assumption of normality were tested with use of 
the nonparametric Mann-Whitney rank-sum test (13). Data 
are expressed as mean values ± SD unless otherwise noted. 
A p value :::; 0.05 was required to demonstrate statistical 
significance. 
Results 
Results of urine testing. Urine testing detected anabolic 
steroids or their metabolites in samples from 12 of the 13 
men who reported that they were using these drugs and in 1 
of the 12 athletes who denied drug use. No drugs were 
detected in the urine sample of one subject who reported 
using nandrolone decanoate, testosterone propionate and 
oxandrolone within 4 days of testing. Another subject denied 
anabolic steroid use but drug testing revealed trace amounts 
of nandrolone metabolites suggesting prior anabolic steroid 
use. These two subjects were eliminated from further anal-
ysis. Only 19 (66%) of 29 declared drugs were actually 
detected by urine testing in athletes reporting use of a 
specific anabolic steroid (Table 1), whereas 7 (58%) of the 12 
drug users provided urine samples containing an unreported 
drug. 
Age, body weight, blood pressure, heart rate and years of 
exercise training. These variables were not significantly dif-
ferent between the men who did and did not use anabolic 
steroids (Table 2). Subjects who were using anabolic steroids 
had done so for 3.3 ± 2.5 years (range 1 to 10). Maximal 
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Table 1. Drugs Reported and Detected in the 12 Men Using 
Anabolic Steroids 
Subjects Reporting 
Use (subjects with 
detected drug) 
Total With 
Drugs Yes No Detected Drug 
Testosterone 2(1) 10 (0) 
Testosterone cypionate 3 (I) 9 (0) 
Testosterone propionate 3 (3) 9 (0) 3 
Boldenone I (0) 11 (I) I 
Nandrolone decanoate 5 (4) 7 (3) 7 
Oxandrolone 3 (2) 9 (0) 2 
Trenbolone I (0) 11 (0) 0 
Norethandrolone I (0) 11 (0) 0 
Oxymetholone 2 (2) 10 (0) 2 
Stanozolol 3 (2) 9 (0) 2 
Drostanolone 3 (2) 9 (0) 2 
Dianabol I (I) 11 (0) I 
Methyltestosterone I (I) 11 (2) 3 
Methenolone 0 (0) 12 (I) 
Total 29 (19) 139 (7) 26 
"Yes" and "No" columns indicate numbers of subjects in the anabolic 
steroid group reporting use or nonuse of a specific drug. Numbers in 
parentheses indicate the number of subjects with positive samples in that 
"Yes" or "No" group. The table does not include two subjects eliminated 
from analysis by drug testing nor does it include the nondrug-using subjects. 
strength was significantly greater for steroid users than for 
nonusers during the bench press and squat and approached 
significance for the bicep curl (p = 0.06), but these perfor-
mances were reported by the athletes and not confirmed by 
actual testing. 
Chamber size, dimensions and systolic function (Table 3). 
Left ventricular and left atrial size did not differ between the 
two groups although left ventricular dimensions were 
slightly greater in the anabolic steroid users. Similarly, left 
Table 2. Physical Characteristics and Training History of the Two 
Study Groups 
Steroid V sers Steroid Nonusers 
(n = 12) (n = 11) 
Age (yr) 23.4 ± 3.5 25.8 ± 6.9 
Height (cm) 173.9 ± 4.8* 180.1 ± 6.1 
Weight (kg) 93.2 ± 11.7 89.0 ± 14.5 
Skinfold sum (mm) 75.7 ± 26.4 95.3 ± 28.5 
Heart rate (beats/min) 82 ± 16.0 80.7 ± 14.3 
Systolic blood pressure 122.8 ± 9.9 124.5 ± 17.3 
(mmHg) 
Diastolic blood pressure 78.0 ± 12.0 80.4 ± 8.4 
(mmHg) 
Training duration (yr) 6.0 ± 3.4 9.8 ± 8.4 
Sessions per week 5.5 ± 0.7 4.9 ± 1.0 
Hours per session 2.0 ± 0.4t 1.3 ± 0.5 
Maximum bench press (kg) 163.5 ± 32.6* 134.3 ± 22.9 
Maximum bicep curl (kg) 83.1 ± 18.4 69.0 ± 15.9 
Maximum squat (kg) 226.7 ± 55.1 * 167.9 ± 37.7 
*p < 0.05, tp < 0.01 based on t test for independent samples. Values are 
mean ± SD. Strength measurements are based on self-reported performance. 
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Table 3. M-Mode Echocardiographic Measurements and Left 
Ventricular Systolic Function in the Two Study Groups 
Steroid V sers Steroid N onusers 
LV ES (mm) 36 ± 3 33 ± 4 
LVED(mm) 57 ± 3 56 ± 5 
RVED(mm) 21 ± 6 21 ± 6 
IVS (mm) 10 ± 2 9 ± I 
LVPW(mm) 8 ± I 8 ± I 
LA(mm) 35 ± 4 37 ± 3 
LV mass (g) 149 ± 27 135 ± 21 
% Fractional shortening 38 ± 5 41 ± 5 
Rate of posterior wall 4.3 ± 1.1 4.0 ± 1.1 
thickening (s- 1) 
Maximal shortening rate (s- 1) -2.7 ± 0.4 -2.8 ± 0.5 
Values are mean ± SD. ED = end-diastole; ES = end-systole; IVS = 
interventricular septal thickness; LA = left atrium; LV = left ventricle; 
LVPW = left ventricular posterior wall thickness; RV = right ventricular. 
ventricular function assessed by percent fractional shorten-
ing and the rate of posterior wall thickening did not differ. 
Percent fractional shortening was lower (38 ± 5% vs. 41 ± 
5%) in the anabolic steroid users, but this difference did not 
achieve statistical significance (p = 0.1). This lower average 
value was due to slightly greater end-diastolic and end-
systolic diameters among the drug users and not to markedly 
lower values for percent fractional shortening in a few 
subjects. 
Diastolic function (Table 4). Left ventricular diastolic 
function assessed by the rate of posterior wall thinning, 
relaxation times, left ventricular filling rate and the Doppler 
pattern of left ventricular inflow was also similar in the users 
and nonusers. Deceleration time is an indirect measure of 
Table 4. Left Ventricular Diastolic Function in the Two 
Study Groups 
Steroid V sers Steroid Non users 
M-mode measurement 
Posterior wall thinning -5.9 ± 1.6 -5.6 ± 2.1 
rate (s- 1) 
Septal thinning rate (s- 1) -4.3 ± 1.8 -4.3 ± 1.6 
Relaxation time (s) 0.06 ± 0.02 0.05 ± 0.02 
Max filling rate (s- 1) 3.1 ± 0.6 3.3 ± 0.5 
Doppler measurements 
E max (cm/s) 81 ± 12 83 ± 12 
Ei(cm) 12 ± 2 13 ± 2 
A max (cm/s) 41 ± 6 41 ± 9 
Ai(cm) 4 ±I 4 ± I 
E maxi A max 2.01 ± 0.49 2.16 ± 0.67 
EJAi 3.24 ± 0.71 3.75 ± 1.35 
Accel T (s) 0.084 ± 0.013 0.071 ± 0.014 
Decel T (s) 0.132 ± 0.029* 0.162 ± 0.015 
Heart rate (beats/min) 67 ± 13 63 ± 11 
*p < 0.01. Values are mean ± SD. Accel T = acceleration time of early 
ventricular filling; Ai = integral of late ventricular filling; A max = maximal 
velocity of late ventricular filling; Decel T = deceleration time of early 
ventricular filling; Ei = integral of early ventricular filling; E max = maximal 
velocity of early ventricular filling. 
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left ventricular compliance and was significantly shorter in 
the anabolic steroid users, a finding that suggests that left 
ventricular compliance was actually better in the anabolic 
steroid users. Nevertheless, this difference was small and no 
other variables suggested improved left ventricular diastolic 
function in the men who were using anabolic steroids. 
Discussion 
Previous studies. Case reports of idiopathic cardiomyop-
athy in athletes who use anabolic steroids (14,15) have raised 
the possibility that these drugs may produce cardiac dys-
function. However, few studies have systematically exam-
ined this possibility. Salke et al. (16) noted no differences in 
left ventricular size and systolic function between 15 athletes 
who were using anabolic steroids and 15 men who were not 
using these drugs. Pearson et al. (7) examined diastolic 
function in 16 weight lifters and 10 control men. Diastolic 
function was similar in the athletes and control subjects but 
Doppler measurements of early diastolic filling were signifi-
cantly reduced in five athletes who reported anabolic steroid 
use, suggesting that these drugs may impair left ventricular 
diastolic function. Urhausen et al. (17) compared 14 weight 
lifters who used anabolic steroids with 7 weight lifters who 
did not use these drugs. Left ventricular septal and posterior 
wall thickness were greater in the steroid group. Systolic 
function did not differ but early diastolic function measured 
by the isovolumetric relaxation time was longer in the drug 
users and correlated with the ratio of left ventricular wall 
thickness to diastolic diameter (r = 0.58, p < 0.05) in this 
group. The maximal rate of early diastolic filling was similar 
in both groups of athletes, however, and the authors (17) 
concluded that greater wall thickness may induce minor 
diastolic dysfunction in athletes who use anabolic steroids. 
Present study: lack of evidence of impaired systolic or 
diastolic function. The present study provided several meth-
odologic improvements over prior reports, yet failed to 
confirm evidence of left ventricular diastolic dysfunction 
with anabolic steroids. Both the echocardiographic and 
Doppler measurements in the present study were performed 
and interpreted by an observer unaware of the athletes' 
group assignment; a variety of diastolic variables were 
determined; and the use or nonuse of anabolic steroids was 
confirmed by urine testing. 
The urine testing produced interesting results. Two sub-
jects, one in each group, were misclassified by personal 
report and were dropped from further study. Only 66% of 
declared drugs were detected in athletes who reported drug 
use and 58% of samples from drug users contained an 
unreported drug. These results suggest that urine testing is 
required for accurate group assignment in studies of individ-
uals who administer anabolic steroids to themselves. In 
addition, it appears that athletes who use anabolic steroids 
frequently do not know the true identity of the drugs. 
Possible risks of anabolic steroids. Our inability to docu-
ment impaired left ventricular systolic and diastolic function 
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in subjects who use anabolic steroids does not imply that 
cardiac effects cannot or will not occur. Left ventricular 
percent fractional shortening was slightly reduced (38 ± 5 
vs. 41 ± 5%) in anabolic steroid users in the present study. 
This result did not reach statistical significance (p = 0.1) but 
small differences might have been detectable in a larger 
sample. Oral anabolic steroids such as stanozolol increase 
coronary artery disease risk by reducing high density 
lipoprotein-cholesterol and apolipoprotein A-1 and increas-
ing low density lipoprotein cholesterol and apolipoprotein B 
(18). Several cases of acute myocardial infarction have been 
reported in young subjects who used these drugs (19). 
Guinea pigs, as well as rats, treated with the anabolic steroid 
methandrostenolone (20,21) demonstrate myocardial intra-
cellular edema, mitochondrial swelling, myofibrillar changes 
and cell necrosis. Dogs who received methandienone in 
doses per kilogram of body weight similar to those used by 
athletes demonstrate increased heart weight compared with 
control animals (22). Left ventricular function measured by 
the changing in pressure over time (dP/dt) in response to 
isoproterenol or volume overload is reduced in the treated 
animals (22). Consequently, animal models support the 
possibility that anabolic steroids deleteriously affect cardiac 
morphology and function . Furthermore, as noted by others 
(23), the relative paucity of documented medical complica-
tions among athletes who use anabolic drugs does not imply 
that no complications exist and the ultimate effect of these 
drugs may not be known for years. The present study's 
failure to document differences in cardiac function between 
men who do or do not use anabolic steroids should be 
viewed with similar caution. 
We acknowledge Patty Gadaleta for assisting in data entry, Richard Terry for 
providing advice on statistical analysis and Teres a Silva for preparation of the 
manuscript. 
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